SYS-CAPLIOX Clinical Trial Inoperable liver metastases from colorectal adenocarcinoma ACTRN12617001268336
2 cohorts
Cohort 1: 1st line patients, RAS mutant
Cohort 2: pre-treated or refractory patients, no specific mutation
Exclusion Criteria
Unsuitable vascular anatomy
No measurable disease, per RECIST v1.1
Previous hypersensitivity or allergies associated with 5-FU, oxaliplatin or contrast agents
Grade > 2 peripheral neuropathy
Evidence of ascites, cirrhosis, portal hypotension, main portal venous tumour involvement or main portal venous thrombosis
Significant co-morbidities
Life expectancy ≤ 3 months
Inclusion Criteria
Inoperable liver metastases from colorectal adenocarcinoma
Two cohorts:
Cohort 1: 1st line patients, RAS mutant
Cohort 2: pre-treated or refractory patients, no specific mutation
Fit for repeated general anaesthesia
Cohort 1: CT confirmed non-progressive disease after minimum 4 XELOX or FOLFOX cycles
Limited extrahepatic disease in lungs or lymph nodes
ECOG 0 - 1
Four-week washout period with monoclonal
antibody treatment, i.e. bevacizumab
18 years of age and over